BH4 antagonists and methods related thereto

US9980936B2 · kind B2 · utility

Assignees

• EMORY UNIVERSITY · US
• The Board of Regents of the University of Texas System · US

Inventors

• Xingming Deng · Atlanta, US
• Jia Zhou · Galveston, US
• Chunyong Ding · Shanghai, CN

Key dates

• Filing date: May 5, 2015
• Grant date: May 29, 2018
• Expiry date: May 5, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/24
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure relates to BH4 inhibitors and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.